Home
About Us
About Antengene
Management Team
Board Of Directors
Scientific Advisory Board
Antengene Events
Investors
Company honor
Contact Us
Our Business
Discovery
Development
Manufacturing
Commercialization
Pipeline
Our Products
Newsroom
Partnerships
Partnering with Antengene
Partnership
Investor Relations
Announcements & Circulars
Corporate Governance
Financial Report
Webcast & Presentation
Event Calendar
Investor Contact
Career
Social Responsibility
Working at Antengene
Join Us
简
EN
Company News
Media Report
Year Select
All
All
2021
03
02
01
2020
12
11
10
09
08
07
06
05
04
03
02
01
2019
12
10
09
07
04
02
01
2018
12
09
08
07
06
05
03
02
2017
11
09
08
04
Apr 06, 2022
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
Mar 30, 2022
Baird Biotech Discovery Series-Karyopharm Therapeutics Inc. (KPTI) & Antengene Corporation Limited
Mar 10, 2022
Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting
Mar 02, 2022
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Feb 07, 2022
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037
Jan 24, 2022
ADOPTION OF THE 2022 RESTRICTED SHARE UNIT SCHEME
About Us
About Us
Management Team
Board Of Directors
Scientific Advisory Board
antengene events
Investors
Company honor
Contact Us
Our Business
Discovery
Development
Manufacturing
Commercialization
Pipeline
Newsroom
Partnerships
Partnering with Antengene
Partnership
Investor Relations
Announcements & Circulars
Corporate Governance
Financial Report
Corporate Presentation
Event Calendar
Investor Contact
Career
Social Responsibility
Working at Antengene
Join Us